Suppr超能文献

NVR 3-778 单药治疗及联合聚乙二醇干扰素治疗对携带人源化肝脏和 HBV 感染的 uPA/SCID 小鼠的疗效。

Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.

机构信息

Novira Therapeutics Inc, part of the Janssen Pharmaceutical Companies, Doylestown, Pennsylvania.

PhoenixBio Co., Ltd., Higashi-Hiroshima, Japan.

出版信息

Gastroenterology. 2018 Feb;154(3):652-662.e8. doi: 10.1053/j.gastro.2017.10.017. Epub 2017 Oct 24.

Abstract

BACKGROUND & AIMS: NVR3-778 is a capsid assembly modulator in clinical development. We determined the in vivo antiviral efficacy and effects on innate and endoplasmic reticulum (ER) stress responses of NVR3-778 alone or in combination with pegylated interferon alpha (peg-IFN) and compared with entecavir.

METHODS

We performed 2 studies, with a total of 61 uPA/SCID mice with humanized livers. Mice were infected with a hepatitis B virus (HBV) genotype C preparation; we waited 8 weeks for persistent infection of the human hepatocytes in livers of mice. Mice were then randomly assigned to groups (5 or 6 per group) given vehicle (control), NVR3-778, entecavir, peg-IFN, NVR3-778 + entecavir, or NVR3-778 + peg-IFN for 6 weeks. We measured levels of HB surface antigen, HB e antigen, HBV RNA, alanine aminotransferase, and human serum albumin at different time points. Livers were collected and analyzed by immunohistochemistry; levels of HBV DNA, covalently closed circular DNA, and HBV RNA, along with markers of ER stress and IFN response, were quantified.

RESULTS

Mice given NVR3-778 or entecavir alone for 6 weeks had reduced serum levels of HBV DNA compared with controls or mice given peg-IFN. The largest reduction was observed in mice given NVR3-778 + peg-IFN; in all mice in this group, the serum level of HBV DNA was below the limit of quantification. NVR3-778 and peg-IFN, but not entecavir, also reduced serum level of HBV RNA. The largest effect was obtained in the NVR3-778 + peg-IFN group, in which serum level of HBV RNA was below the limit of quantification. Levels of HB surface antigen and HB e antigen were reduced significantly in only the groups that received peg-IFN. Levels of covalently closed circular DNA did not differ significantly among groups. NVR3-778 was not associated with any significant changes in level of alanine aminotransferase, the ER stress response, or IFN-stimulated genes.

CONCLUSIONS

NVR3-778 has high antiviral activity in mice with humanized livers and stable HBV infection, reducing levels of serum HBV DNA and HBV RNA. Entecavir reduced levels of serum HBV DNA, but had no effect on HBV RNA. The combination of NVR3-778 and peg-IFN prevented viral replication and HBV RNA particle production to a greater extent than each compound alone or entecavir.

摘要

背景与目的

NVR3-778 是一种正在临床开发中的衣壳组装调节剂。我们测定了 NVR3-778 单独或与聚乙二醇化干扰素 alpha(peg-IFN)联合使用时的体内抗病毒疗效以及对固有和内质网(ER)应激反应的影响,并与恩替卡韦进行了比较。

方法

我们进行了两项研究,共纳入 61 只具有人源化肝脏的 uPA/SCID 小鼠。小鼠感染乙型肝炎病毒(HBV)基因型 C 制剂;我们等待 8 周,使小鼠肝脏中的人肝细胞持续感染。然后,小鼠被随机分为 5 或 6 组(每组 5 或 6 只),分别给予载体(对照)、NVR3-778、恩替卡韦、peg-IFN、NVR3-778+恩替卡韦或 NVR3-778+peg-IFN 治疗 6 周。我们在不同时间点测量乙型肝炎表面抗原、乙型肝炎 e 抗原、HBV RNA、丙氨酸氨基转移酶和人血清白蛋白的水平。收集肝脏并进行免疫组织化学分析;定量检测 HBV DNA、共价闭合环状 DNA 和 HBV RNA 以及 ER 应激和 IFN 反应标志物的水平。

结果

与对照组或给予 peg-IFN 的小鼠相比,给予 NVR3-778 或恩替卡韦单独治疗 6 周的小鼠血清 HBV DNA 水平降低。在给予 NVR3-778+peg-IFN 的小鼠中观察到最大的降低;在该组的所有小鼠中,HBV DNA 的血清水平低于定量下限。NVR3-778 和 peg-IFN 均可降低血清 HBV RNA 水平,而恩替卡韦则不能。在 NVR3-778+peg-IFN 组中观察到最大的效果,该组中 HBV RNA 的血清水平低于定量下限。仅接受 peg-IFN 的组中,HB 表面抗原和 HB e 抗原的水平显著降低。各组中环化 DNA 水平无显著差异。NVR3-778 与丙氨酸氨基转移酶水平、ER 应激反应或 IFN 刺激基因的任何显著变化均无关。

结论

NVR3-778 对具有人源化肝脏和稳定 HBV 感染的小鼠具有很强的抗病毒活性,可降低血清 HBV DNA 和 HBV RNA 水平。恩替卡韦降低了血清 HBV DNA 水平,但对 HBV RNA 没有影响。NVR3-778 与 peg-IFN 的联合使用在阻止病毒复制和 HBV RNA 颗粒生成方面的效果大于单独使用或与恩替卡韦联合使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验